Somatic activating mutations in JAK2 V617F located at 9p24 are very common in myeloproliferative neoplasms (MPN) and have been associated with an increased incidence of thrombosis, hemorrhage, and fibrosis [1,2,3]. This evidence concerns the gene JAK2 and myeloproliferative disorder.